Domenico Mavilio is group leader at Humanitas Research Hospital, in Milan, where he leads the Clinical and Experimental Immunology Lab. He is also full professor of translational medicine at the Department of Medical Biotechnologies and Translational Medicine of the Medical School of the University of Milan.
Mavilio graduated as M.D. and completed his residency program in Internal Medicine and Respiratory Medicine at the Medical School of Genova University. He then obtained his Ph.D. in Clinical and Experimental Immunology within a joint program between the University of Genova (Italy) and the National Institutes of Health (USA). He was then appointed as Research Fellow at NIH, where he spent 9 years before going back to Italy, at Humanitas Research Hospital, where he was appointed group leader of the Clinical and Experimental Immunology Lab. He currently serves as a full professor of translational medicine at Medical School of the University of Milan “La Statale”.
As physician, prof. Mavilio focuses his clinical activities on immunological disorders and hematologic malignancies. As a scientist, he handles research projects of translational medicine from the “bed-to bench” side aimed to study the pathogenesis and the cure of immunologic diseases. As of January 2023, he published 132 articles on peer reviewed scientific journals, several book chapters and has an H-Index of 42, with a total number of citations of 6766 (Scopus).
Prof. Mavilio also currently serves as Adjunct Investigator at NIH and is a board member of Ph.D. Program in Experimental Medicine of Milan University. He is affiliated with several national and international scientific societies, is a member of the editorial boards of several international peer-reviewed scientific journals, deputy editor of the Journal of Leukocyte Biology (JLB), past elected member of the council of the Society of Leukocyte Biology (SLB), present elected member Italian Society of Immunology (SIICA), member of the ethical committee of the University of Milan “La Statale” .
Mavilio’s research is funded by competitive grants from Italian Ministry of Health, Fondazione Cariplo, Fondazione Umberto Veronesi, Associazione Italiana per la Ricerca sul Cancro (AIRC) and the European Union.